Evidence map›Paper›PMID 31842769›Full record

Observational studyBMC cardiovascular disorders2019

Myocardial characterization in pre-dialysis chronic kidney disease: a study of prevalence, patterns and outcomes.

Anna M Price, Manvir K Hayer, Ravi Vijapurapu, Saad A Fyyaz, William E Moody, Charles J Ferro, Jonathan N Townend, Richard P Steeds, Nicola C Edwards

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in BMC cardiovascular disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. TCardiac failure review · 2022
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Anna M PriceBirmingham Cardio-Renal Group, Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.ORCID 0000-0003-0952-7688
Manvir K HayerBirmingham Cardio-Renal Group, Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.
Ravi VijapurapuDepartment of Cardiology, Queen Elizabeth Hospital, Birmingham, UK.
Saad A FyyazDepartment of Cardiology, Queen Elizabeth Hospital, Birmingham, UK.
William E MoodyBirmingham Cardio-Renal Group, Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.
Charles J FerroBirmingham Cardio-Renal Group, Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.
Jonathan N TownendBirmingham Cardio-Renal Group, Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.
Richard P SteedsBirmingham Cardio-Renal Group, Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.
Nicola C EdwardsBirmingham Cardio-Renal Group, Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK. NicolaEd@adhb.govt.nz.
Queen Elizabeth Hospital Birmingham · GBGreen Lane Hospital · GB

Funding

British Heart Foundation FS/16/73/32314British Heart Foundation PG/15/117/31961Wellcome Trust
6 · The paper itself

Abstract

backgroundLate gadolinium enhancement (LGE) using cardiac magnetic resonance (CMR) characterizes myocardial disease and predicts an adverse cardiovascular (CV) prognosis. Myocardial abnormalities, are present in early chronic kidney disease (CKD). To date there are no data defining prevalence, pattern and clinical implications of LGE-CMR in CKD.

methodsPatients with pre-dialysis CKD (stage 2-5) attending specialist renal clinics at University Hospital Birmingham (UK) who underwent gadolinium enhanced CMR (1.5 T) between 2005 and 2017 were included. The patterns and presence (LGEpos) / absence (LGEneg) of LGE were assessed by two blinded observers. Association between LGE and CV outcomes were assessed.

resultsIn total, 159 patients received gadolinium (male 61%, mean age 55 years, mean left ventricular ejection fraction 69%, left ventricular hypertrophy 5%) with a median follow up period of 3.8 years [1.04-11.59]. LGEpos was present in 55 (34%) subjects; the patterns were: right ventricular insertion point n = 28 (51%), mid wall n = 18 (33%), sub-endocardial n = 5 (9%) and sub-epicardial n = 4 (7%). There were no differences in left ventricular structural or functional parameters with LGEpos. There were 12 adverse CV outcomes over follow up; 7 of 55 with LGEpos and 5 of 104 LGEneg. LGEpos was not predicted by age, gender, glomerular filtration rate or electrocardiographic abnormalities.

conclusionsIn a selected cohort of subjects with moderate CKD but low CV risk, LGE was present in approximately a third of patients. LGE was not associated with adverse CV outcomes. Further studies in high risk CKD cohorts are required to assess the role of LGE with multiplicative risk factors.

Indexed as

Magnetic Resonance ImagingAdultAgedCause of DeathContrast MediaEnglandFemaleFibrosisGadolinium DTPAHumansHypertrophy, Left VentricularMaleMiddle AgedOrganometallic CompoundsPredictive Value of TestsPrevalenceContrast MediagadobutrolGadolinium DTPAOrganometallic CompoundsCardiac magnetic resonanceChronic kidney diseaseFibrosisGadolinium

Identifiers

PMID31842769
PMCPMC6916031
OpenAlexW2995239688

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.